The principal aim of the Doernbecher Children’s Hospital Development Therapeutics program is to evaluate novel agents for the treatment of pediatric cancer through early phase clinical trials. We conduct Phase I and Phase II trials of potentially promising new drugs for the treatment of all types of childhood cancer. Doernbecher is one of 21 select institutions throughout North America who comprise the NCI-funded Children’s Oncology Group Phase I Consortium. Through our participation in COG early phase trials, industry-sponsored trials, and investigator-initiated studies, we hope to find better therapies for the treatment of childhood cancer.
The principal investigator of the Doernbecher Children’s Hospital Development Therapeutics program is pediatric hematologist-oncologist, Dr. Suman Malempati. For a recent discussion by Dr. Malempati on a targeted therapy for childhood sarcomas, see the November 16th NCI Cancer Bulletin. Integral, too, to the Development Therapeutics program is Rae Acosta, RN.